Edward E. Kadel

11.3k citations
37 papers · 858 · 1 hit paper · h-index 15

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
  • Immunology top 10%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

Co-authors
Sanjeev Mariathasan (18 shared papers)Thomas Powles (10 shared papers)Kobe Yuen (12 shared papers)Charles G. Drake (3 shared papers)Piotr J. Wysocki (2 shared papers)Dana E. Rathkopf (2 shared papers)Gary L. Buchschacher (2 shared papers)Patrick Williams (3 shared papers)
Journals
Journal of Clinical Oncology (9 papers)Cancer Research (6 papers)Clinical Cancer Research (3 papers)Blood (3 papers)Cancer Immunology Research (2 papers)
Partner nations
United StatesUnited KingdomFrance

In The Last Decade

Edward E. Kadel

35 papers receiving 837 citations

Edward E. Kadel's Hit Papers

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial 2022 · 172 citations
1720+1+2Years since publication50100150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2022 Nature Medicine

Peers

Edward E. Kadel
Comparison fields: 5 of 69
  • Oncology 392
  • Immunology 246
  • Pulmonary and Respiratory Medicine 274
  • Cancer Research 84
  • Genetics 57
Replace Felix Frenkel with:
Felix Frenkel United States
Samir Tawadros Germany
Scott D. Brown Canada
Kaiming Sun United States
Raed Samara United States
Josue Samayoa United States
Cristina Mastini Italy
Huqun Japan
Hyunchul Jung South Korea
Anshuman Panda United States
Edward E. Kadel relative to Felix Frenkel United States Felix Frenkel's profile →
Citations per field
00.5×5×10×15×20×23×
Felix Frenkel · 1×
Citations per year

Countries citing papers authored by Edward E. Kadel

Since Specialization
Citations

This map shows the geographic impact of Edward E. Kadel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward E. Kadel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward E. Kadel more than expected).

Fields of papers citing papers by Edward E. Kadel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward E. Kadel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward E. Kadel. The network helps show where Edward E. Kadel may publish in the future.

Co-authors

The 25 scholars most cited alongside Edward E. Kadel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Edward E. Kadel Line = papers co-authored together Edward E. Kadel links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
Nature Medicine ·Thomas Powles, Kobe Yuen, Silke Gillessen, Edward E. Kadel, Dana E. Rathkopf, Nobuaki Matsubara, Charles G. Drake, Karim Fizazi, Josep M. Piulats, Piotr J. Wysocki, Gary L. Buchschacher, B. Yа. Alekseev, Begoña Mellado, Bogusława Karaszewska, Jennifer Doss, Grozdana Rasuo, Asim Datye, Sanjeev Mariathasan, Patrick Williams, Christopher J. Sweeney
Hit paper breakdown →		2022172
2
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Blood ·Mohammad Luqman, Sha Klabunde, Karen Lin, Georgios Georgakis, Anu Cherukuri, Jocelyn Holash, Cheryl Goldbeck, Xiaomei Xu, Edward E. Kadel, Sang Hoon Lee, Sharon L. Aukerman, Bahija Jallal, Natasha Aziz, Wen-Kai Weng, William G. Wierda, Susan O’Brien, Anas Younes
200885
3
Anchored Reference Loci in Loblolly Pine (Pinus taeda L.) for Integrating Pine Genomics
Genetics ·Garth Brown, Edward E. Kadel, Daniel L. Bassoni, Kristine Kiehne, Berhanu Temesgen, J. P. van Buijtenen, Mitchell M. Sewell, Kimberly A. Marshall, (unknown)
200181
4
PD-L1 and tumor-associated macrophages in de novo DLBCL
Blood Advances ·Ronald McCord, Christopher R. Bolen, Hartmut Koeppen, Edward E. Kadel, Mikkel Z. Oestergaard, Tina Nielsen, Laurie H. Sehn, Jeffrey M. Venstrom
201960
5
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Clinical Cancer Research ·Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles
202155
6
Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Cancer Research ·Christopher J. Sweeney, Silke Gillessen, Dana E. Rathkopf, Nobuaki Matsubara, Charles G. Drake, Karim Fizazi, Josep M. Piulats, Piotr J. Wysocki, Gary L. Buchschacher, Jennifer Doss, Sanjeev Mariathasan, Edward E. Kadel, Kobe Yuen, Asim Datye, Grozdana Rasuo, Darren Tayama, Patrick Williams, Thomas Powles
202048
7
Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.
Journal of Clinical Oncology ·Fatema A. Legrand, David R. Gandara, Sanjeev Mariathasan, Thomas Powles, Xian He, Wei Zhang, Suchit Jhunjhunwala, Dorothee Nickles, Richard Bourgon, Erica Schleifman, Sarah Paul, Edward E. Kadel, Marcin Kowanetz, Craig Cummings, Yan Li, David Fabrizio, Eric Peters, Priti S. Hegde, Lukas C. Amler, David S. Shames
201845
8
Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist
Drug Metabolism and Disposition ·Harvey Wong, Stephen E. Gould, Nageshwar Budha, Walter C. Darbonne, Edward E. Kadel, Hank La, Bruno Alicke, Jason Halladay, Rebecca J. Erickson, Chia C. Portera, Anthony W. Tolcher, J. Infante, Michael Mamounas, John A. Flygare, Cornelis E. C. A. Hop, Wayne J. Fairbrother
201344
9
A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research ·Lawrence Fong, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka N. Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E. Kadel, Kobe Yuen, Asim Datye, Andrew J. Armstrong, Daniel P. Petrylak
202138
10
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
Journal of Clinical Oncology ·Jonathan E. Rosenberg, Daniel P. Petrylak, Michiel Simon Van Der Heijden, Andrea Necchi, Peter H. O’Donnell, Yohann Loriot, Margitta Retz, José Luis Perez‐Gracia, Joaquim Bellmunt, Petros Grivas, Richard W. Joseph, Lawrence Fong, Edward E. Kadel, Zachary Boyd, Dorothee Nickles, Garrett M. Frampton, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, Thomas Powles
201636
11
Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
Journal of Clinical Oncology ·Thomas Powles, Yohann Loriot, Alain Ravaud, Nicholas J. Vogelzang, Ignacio Durán, Margitta Retz, Ugo De Giorgi, Stéphane Oudard, Aristotelis Bamias, Hartmut Koeppen, Ning Leng, Edward E. Kadel, Priti S. Hegde, Na Cui, Xiaodong Shen, Christina Louise Derleth, Marjorie C. Green, Romain Banchereau, Sanjeev Mariathasan, Michiel Simon Van Der Heijden
201835
12
Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.
Journal of Clinical Oncology ·Matt D. Galsky, Romain Banchereau, Habib Hamidi, Ning Leng, Will Harris, Peter H. O’Donnell, Edward E. Kadel, Kobe Yuen, Dexter X. Jin, Hartmut Koeppen, Darren Tayama, Enrique Grande, José Ángel Arranz, Maria De Santis, Ian D. Davis, Eiji Kikuchi, Xiaodong Shen, Aristotelis Bamias, Sanjeev Mariathasan
202020
13
In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales
Briefings in Bioinformatics ·Jieming Chen, Shravan Madireddi, Deepti R. Nagarkar, Maciej Migdał, Jason A. Vander Heiden, Diana Chang, Kiran Mukhyala, Suresh Selvaraj, Edward E. Kadel, Matthew J. Brauer, Sanjeev Mariathasan, Julie Hunkapiller, Suchit Jhunjhunwala, Matthew L. Albert, Christian Hammer
202016
14
A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology ·Joseph W. Kim, David R. Shaffer, Christophe Massard, Thomas Powles, Lauren C. Harshman, Fadi S. Braiteh, Paul Conkling, Indrani Sarkar, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Christina Schiff, Marcella Fassò, Susheela Carroll, Daniel P. Petrylak
201815
15
Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial
Nature Communications ·Jay Jasti, Hua Zhong, Vandana Panwar, Vipul Jarmale, Jeffrey Miyata, Deyssy Carrillo, Alana Christie, Dinesh Rakheja, Zora Modrusan, Edward E. Kadel, Niha Beig, Mahrukh Huseni, James Brugarolas, Payal Kapur, Satwik Rajaram
202514
16
Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML
Blood ·Monique Dail, Long Yang, Cherie Green, Connie Ma, Alberto Robert, Edward E. Kadel, Harmut Koeppen, Joanne I. Adamkewicz, John Byon, Joseph Woodard, Scott J. Rodig, Jeffrey M. Venstrom
201612
17
Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
Journal of Clinical Oncology ·Michael J. Morris, Lawrence Fong, Daniel P. Petrylak, Oliver Sartor, Celestia S. Higano, Lance C. Pagliaro, Ajjai Alva, Leonard J. Appleman, Winston Tan, Ulka N. Vaishampayan, Raphaelle Porcu, Darren Tayama, Edward E. Kadel, Kobe Yuen, Asim Datye, Andrew J. Armstrong
202012
18
Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients
Cancer Research ·Daniel D. Von Hoff, Charles M. Rudin, Patricia LoRusso, Mitesh J. Borad, Ronald L. Korn, Elisabeth I. Heath, Robert L. Yauch, Walter C. Darbonne, Edward E. Kadel, Kenn L. Zerivitz, Lisa E Nelson, Howard Mackey, James C. Marsters, Frédéric J. de Sauvage, Jennifer A. Low
200811
19
Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)
Journal for ImmunoTherapy of Cancer ·Thomas Powles, Dorothee Nickles, Eliezer M. Van Allen, Colombe Chappey, Wei Zou, Marcin Kowanetz, Edward E. Kadel, Mitchell Denker, Zachary Boyd, Nicholas J. Vogelzang, Joseph Kim, Joaquim Bellmunt, Yohann Loriot, Charles G. Drake, Carol O’Hear, Marcella Fassò, Priti S. Hegde, Sanjeev Mariathasan
201511
20
Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.
Journal of Clinical Oncology ·Scott Gettinger, Marcin Kowanetz, Hartmut Koeppen, Ignacio I. Wistuba, Mark Kockx, Edward E. Kadel, Naiyer A. Rizvi, Alexander I. Spira, Fred R. Hirsch, Zachary Boyd, Mitchell Denker, Alexandra H. Minn, David S. Shames, Alan N. Sandler, Daniel S. Chen, Priti S. Hegde, David R. Spigel
201510

About Edward E. Kadel

Edward E. Kadel is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Immunology, having authored 37 papers that have together received 858 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (22 papers), Bladder and Urothelial Cancer Treatments (13 papers), Prostate Cancer Treatment and Research (10 papers), Ferroptosis and cancer prognosis (6 papers), Cancer Genomics and Diagnostics (4 papers), Renal cell carcinoma treatment (4 papers), Immunotherapy and Immune Responses (4 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). The work is most often cited by research in Oncology (392 citations), Immunology (246 citations), Pulmonary and Respiratory Medicine (274 citations), Cancer Research (84 citations) and Genetics (57 citations). Edward E. Kadel has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Sanjeev Mariathasan, Thomas Powles, Kobe Yuen, Charles G. Drake, Piotr J. Wysocki, Dana E. Rathkopf, Gary L. Buchschacher, Patrick Williams, Josep M. Piulats and Nobuaki Matsubara. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Blood and Cancer Immunology Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Felix FrenkelBreakdown of academic impact, for papers by Samir TawadrosBreakdown of academic impact, for papers by Scott D. BrownBreakdown of academic impact, for papers by Kaiming SunBreakdown of academic impact, for papers by Raed SamaraBreakdown of academic impact, for papers by Josue SamayoaBreakdown of academic impact, for papers by Cristina MastiniBreakdown of academic impact, for papers by HuqunBreakdown of academic impact, for papers by Hyunchul JungBreakdown of academic impact, for papers by Anshuman Panda